Yoshida Ryo, Matsuura Takashi, Hijikawa Ken, Yanagida Hidesuke, Kitade Hiroaki, Takada Hideho, Kwon A-Hon
Dept. of Surgery, Kansai Medical University, Takii Hospital, Japan.
Gan To Kagaku Ryoho. 2012 Oct;39(10):1575-7.
A 68-year-old man had undergone right hemicolectomy of ascending colon cancer with multiple liver metastases. This case of k-ras status on the cancer tissue also showed wild type. Chemotherapy with panitumumab and 5-FU/LV/irinotecan (FOLFIRI)regimen was performed after the resection of the ascending colon cancer. After seven curses of treatment, metastatic liver tumors were reduced considerably(PR). Liver resection(left hepatic lobectomy and partial resection of S4 and S5)and radiofrequency ablation therapy were performed. Recently, chemotherapy has improved overall survival of initially unresectable patients by allowing tumor downstaging and complete resection. Combination chemotherapy using panitumumab, and FOLFIRI plus operation is a candidate as a standard treatment strategy for multiple liver metastases of colon cancer.
一名68岁男性因升结肠癌伴多发肝转移接受了右半结肠切除术。该癌症组织的k-ras状态也显示为野生型。升结肠癌切除术后采用帕尼单抗和5-氟尿嘧啶/亚叶酸钙/伊立替康（FOLFIRI）方案进行化疗。经过七个疗程的治疗，转移性肝肿瘤明显缩小（部分缓解）。随后进行了肝切除术（左肝叶切除及S4和S5部分切除）和射频消融治疗。近来，化疗通过使肿瘤降期并实现完整切除，提高了初始不可切除患者的总生存率。使用帕尼单抗、FOLFIRI联合手术的联合化疗是结肠癌多发肝转移标准治疗策略的候选方案。
